The Global Hepatic Encephalopathy Market Is Witnessing High Growth

 

Hepatic encephalopathy (HE) is the leading cause of death in patients with acute liver failure, as well as those with liver cirrhosis and end stage liver disease. The person suffering from hepatic encephalopathy loses the ability to metabolise ammonia, resulting in ammonia buildup in various tissues and organs of the body. Furthermore, ammonia crosses the blood-brain barrier, causing neurocognitive impairment. Hepatic encephalopathy is divided into two types: covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE), with overt hepatic encephalopathy being associated with a higher rate of mortality and a lower quality of life than covert hepatic encephalopathy (CHE).

Hepatic Encephalopathy Market is a brain disorder that most commonly affects people who have chronic liver disease. Its complications may include brain dysfunction, which may include impaired memory, intellectual impairment, personality changes, and loss of consciousness (coma). Overt hepatic encephalopathy is characterized by obvious, outward signs and symptoms in affected individuals.

Hepatic Encephalopathy Market  is a brain disorder that occurs in people who have liver disease. Hepatic Encephalopathy is a significant contributor to morbidity in patients with liver disease, presenting a spectrum of neuropsychiatric symptoms ranging from mild fluctuating cognitive impairment to coma.

The current Hepatic Encephalopathy Market includes therapies such as The two main types of therapies for Hepatic Encephalopathy are nonabsorbable disaccharides (lactitol and lactulose) and nonabsorbable antibiotics (rifaximin). Nonabsorbable disaccharides are the first-line treatment for acute or chronic Hepatic Encephalopathy (lactulose or lactitol). Oral antibiotics (neomycin, metronidazole, and rifaximin) are second-line agents that can reduce urease-producing bacteria in the intestines, resulting in decreased ammonia production and absorption through the gastrointestinal tract. Salix Pharmaceuticals' Xifaxan (rifaximin) tablets are approved for the prevention of recurrent Overt Hepatic Encephalopathy (OHE) in adults.

Key Players

ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V., Abbott Laboratories, and QR Science and Technology Development Co. Ltd. are among the major players in the global hepatic encephalopathy market.